BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

...treat postherpetic neuralgia neuropathic pain. At least one company is still pursuing the target. The Sylentis S.A....
...pain, in Sjögren syndrome patients with good local and systemic tolerance in Phase III testing. Sylentis...
BioCentury | Jun 9, 2017
Clinical News

Sylentis starts Phase III of SYL1001 to treat dry eye disease

...safety. SYL1001 comprises short interfering RNAs (siRNAs) against transient receptor potential vanilloid 1 (TRPV1; VR1). Sylentis S.A....
...staining (CFS) total scores and conjunctival hyperemia scores; safety Status: Phase III started Milestone: NA Alicia Parker SYL1001 Sylentis S.A. Transient...
BioCentury | Mar 21, 2016
Clinical News

SYL1001: Phase II data

...presented at the Association for Research in Vision and Ophthalmology meeting in Seattle in May. Sylentis S.A....
BioCentury | Oct 12, 2015
Clinical News

Bamosiran: Phase II data

...mmHg. Bamosiran was well tolerated. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A....
BioCentury | Oct 24, 2013
Cover Story

A platform for RNA

...LSE:GSK; NYSE:GSK) Collaboration on RNAi technology called VaxiRNA to speed vaccine production Undisclosed Nov. 2011 Sylentis S.A....
...I SBI Biotech Co. Ltd. siRNA Phase II Silence Therapeutics plc (LSE:SLN) siRNA Phase II Sylentis S.A....
BioCentury | Jun 10, 2013
Clinical News

SYL040012: Phase IIa data

...met the primary endpoint of reducing IOP from baseline vs. placebo. SLY040012 was well tolerated. Sylentis...
...next clinical trial will be planned after "all of the trial's variables have been analyzed." Sylentis S.A....
BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...for an undisclosed RNAi therapeutic product ND Jan-12 Sylentis S.A. subsidiary of Zeltia S.A. (Madrid:ZEL) Option Sylentis...
BioCentury | Mar 11, 2013
Clinical News

SYL1001: Phase II started

...Phase II trial to evaluate topical SYL1001 once daily for 10 days in 60 patients. Sylentis S.A....
BioCentury | Jun 18, 2012
Clinical News

SYL040012: Phase II started

...14 days in 80 patients. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A....
BioCentury | Nov 21, 2011
Company News

Alnylam, Zeltia deal

...Alnylam granted Zeltia's Sylentis S.A. subsidiary a non-exclusive option for a license to develop and commercialize a...
Items per page:
1 - 10 of 13
BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

...treat postherpetic neuralgia neuropathic pain. At least one company is still pursuing the target. The Sylentis S.A....
...pain, in Sjögren syndrome patients with good local and systemic tolerance in Phase III testing. Sylentis...
BioCentury | Jun 9, 2017
Clinical News

Sylentis starts Phase III of SYL1001 to treat dry eye disease

...safety. SYL1001 comprises short interfering RNAs (siRNAs) against transient receptor potential vanilloid 1 (TRPV1; VR1). Sylentis S.A....
...staining (CFS) total scores and conjunctival hyperemia scores; safety Status: Phase III started Milestone: NA Alicia Parker SYL1001 Sylentis S.A. Transient...
BioCentury | Mar 21, 2016
Clinical News

SYL1001: Phase II data

...presented at the Association for Research in Vision and Ophthalmology meeting in Seattle in May. Sylentis S.A....
BioCentury | Oct 12, 2015
Clinical News

Bamosiran: Phase II data

...mmHg. Bamosiran was well tolerated. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A....
BioCentury | Oct 24, 2013
Cover Story

A platform for RNA

...LSE:GSK; NYSE:GSK) Collaboration on RNAi technology called VaxiRNA to speed vaccine production Undisclosed Nov. 2011 Sylentis S.A....
...I SBI Biotech Co. Ltd. siRNA Phase II Silence Therapeutics plc (LSE:SLN) siRNA Phase II Sylentis S.A....
BioCentury | Jun 10, 2013
Clinical News

SYL040012: Phase IIa data

...met the primary endpoint of reducing IOP from baseline vs. placebo. SLY040012 was well tolerated. Sylentis...
...next clinical trial will be planned after "all of the trial's variables have been analyzed." Sylentis S.A....
BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...for an undisclosed RNAi therapeutic product ND Jan-12 Sylentis S.A. subsidiary of Zeltia S.A. (Madrid:ZEL) Option Sylentis...
BioCentury | Mar 11, 2013
Clinical News

SYL1001: Phase II started

...Phase II trial to evaluate topical SYL1001 once daily for 10 days in 60 patients. Sylentis S.A....
BioCentury | Jun 18, 2012
Clinical News

SYL040012: Phase II started

...14 days in 80 patients. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A....
BioCentury | Nov 21, 2011
Company News

Alnylam, Zeltia deal

...Alnylam granted Zeltia's Sylentis S.A. subsidiary a non-exclusive option for a license to develop and commercialize a...
Items per page:
1 - 10 of 13